Tue, Jul 29, 2014, 1:40 PM EDT - U.S. Markets close in 2 hrs 20 mins

Recent

% | $
Click the to save as a favorite.

Avanir Pharmaceuticals, Inc. Message Board

  • steveprofes steveprofes Feb 11, 2013 10:58 PM Flag

    3rd party Medicare D coverage

    I'm being told by pharmacists providing meds to long tterm care homes that Medicare D prescription drug plans are not covering Neudexa. This is not good news.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The big jump in scripts in association with a rule specific to Medicare D and LTC pharmacies would argue otherwise.

    • I believe Avanir said that Neudexta is covered by Part D for most companies. My guess is that in the case of long term care homes there are many off lable prescriptions being written and Medicare Part D generally doesn't cover for off-label use, particularly for an expensive drug like Neudexta and even when it is covered it is likely to have a high co-pay, because it is an expensive drug. In addition to that, I don't know at what point that you talked to pharmacists, but towards the end of the year, many very sick people, who take a lot of drugs are probably in the "donut hole". I would guess that any and/or all of the above may be the case with Neudexta.

      The good news is that if there are problems with coverage due to off-label use in long term care facilities, it is also a venue for making more doctors aware of the off-label potential of Neudexta, particularly as a way of safely controlling some of the patients with behavior problems without interfering with their quality of life or risking health issues. This may become increasingly popular now that they have the safety results back

      Sentiment: Buy

      • 1 Reply to intpmom17
      • "particularly as a way of safely controlling some of the patients with behavior problems without interfering with their quality of life or risking health issues. This may become increasingly popular now that they have the safety results back"
        The vast majority of physicians are not going to be using Nuedexta, a drug with significant safety issues for the unproven indication of "controlling behavior problems".
        This will not become "increasingly popular" unless there is a large study that shows efficacy--and agitation in dementia is the least likely group to try to prove efficacy. As for having "safety results back", what safety results?

 
AVNR
5.30+0.10(+1.92%)1:40 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.